AIM: This study evaluates the acute toxicity outcome in patients treated with RapidArc for localized prostate cancer. BACKGROUND: Modern technologies allow the delivery of high doses to the prostate while lowering the dose to the neighbouring organs at risk. Whether this dosimetric advantage translates into clinical benefit is not well known. MATERIALS AND METHODS: Between December 2009 and May 2012, 45 patients with primary prostate adenocarcinoma were treated using RapidArc. All patients received 1.8 Gy per fraction, the median dose to the prostate gland, seminal vesicles, pelvic lymph nodes and surgical bed was 80 Gy (range, 77.4-81 Gy), 50.4 Gy, 50.4 Gy and 77.4 Gy (range, 75.6-79.2 Gy), respectively. RESULTS: The time between the last session and the last treatment follow up was a median of 10 months (range, 3-24 months). The incidence of grade 3 acute gastrointestinal (GI) and genitourinary (GU) toxicity was 2.2% and 15.5%, respectively. Grade 2 acute GI and GU toxicity occurred in 30% and 27% of patients, respectively. No grade 4 acute GI and GU toxicity were observed. Older patients (>median) or patients with V60 higher than 35% had significantly higher rates of grade ≥2 acute GI toxicity compared with the younger ones. CONCLUSIONS: RapidArc in the treatment of localized prostate cancer is tolerated well with no Grade >3 GI and GU toxicities. Older patients or patients with higher V60 had significantly higher rates of grade ≥2 acute GI toxicity. Further research is necessary to assess definitive late toxicity and tumour control outcome.
AIM: This study evaluates the acute toxicity outcome in patients treated with RapidArc for localized prostate cancer. BACKGROUND: Modern technologies allow the delivery of high doses to the prostate while lowering the dose to the neighbouring organs at risk. Whether this dosimetric advantage translates into clinical benefit is not well known. MATERIALS AND METHODS: Between December 2009 and May 2012, 45 patients with primary prostate adenocarcinoma were treated using RapidArc. All patients received 1.8 Gy per fraction, the median dose to the prostate gland, seminal vesicles, pelvic lymph nodes and surgical bed was 80 Gy (range, 77.4-81 Gy), 50.4 Gy, 50.4 Gy and 77.4 Gy (range, 75.6-79.2 Gy), respectively. RESULTS: The time between the last session and the last treatment follow up was a median of 10 months (range, 3-24 months). The incidence of grade 3 acute gastrointestinal (GI) and genitourinary (GU) toxicity was 2.2% and 15.5%, respectively. Grade 2 acute GI and GU toxicity occurred in 30% and 27% of patients, respectively. No grade 4 acute GI and GU toxicity were observed. Older patients (>median) or patients with V60 higher than 35% had significantly higher rates of grade ≥2 acute GI toxicity compared with the younger ones. CONCLUSIONS: RapidArc in the treatment of localized prostate cancer is tolerated well with no Grade >3 GI and GU toxicities. Older patients or patients with higher V60 had significantly higher rates of grade ≥2 acute GI toxicity. Further research is necessary to assess definitive late toxicity and tumour control outcome.
Authors: Ayal A Aizer; Nicole S Anderson; Steven C Oh; James B Yu; Anne M McKeon; Roy H Decker; Richard E Peschel Journal: Int J Radiat Oncol Biol Phys Date: 2010-05-06 Impact factor: 7.038
Authors: Sofie De Langhe; Kim De Ruyck; Piet Ost; Valérie Fonteyne; Joke Werbrouck; Gert De Meerleer; Wilfried De Neve; Hubert Thierens Journal: Int J Radiat Oncol Biol Phys Date: 2012-06-02 Impact factor: 7.038
Authors: B S Teh; W Y Mai; B M Uhl; M E Augspurger; W H Grant; H H Lu; S Y Woo; L S Carpenter; J K Chiu; E B Butler Journal: Int J Radiat Oncol Biol Phys Date: 2001-03-01 Impact factor: 7.038
Authors: David Palma; Emily Vollans; Kerry James; Sandy Nakano; Vitali Moiseenko; Richard Shaffer; Michael McKenzie; James Morris; Karl Otto Journal: Int J Radiat Oncol Biol Phys Date: 2008-05-01 Impact factor: 7.038
Authors: Jose Luis Lopez Guerra; Nicolas Isa; Raul Matute; Moises Russo; Fernando Puebla; Michelle Miran Kim; Alberto Sanchez-Reyes; Cesar Beltran; Javier Jaen; Celine Bourgier; Hugo Marsiglia Journal: Clin Transl Oncol Date: 2012-07-24 Impact factor: 3.405
Authors: Suneil Jain; D Andrew Loblaw; Gerard C Morton; Cyril Danjoux; Ewa Szumacher; William Chu; Hans T Chung; Danny Vesprini; Arjun Sahgal; Liying Zhang; Andrea Deabreu; Patrick C F Cheung Journal: Radiother Oncol Date: 2012-11-22 Impact factor: 6.280
Authors: Sreeja Sarojini; Andrew Pecora; Natasha Milinovikj; Joseph Barbiere; Saakshi Gupta; Zeenathual M Hussain; Mehmet Tuna; Jennifer Jiang; Laura Adrianzen; Jaewook Jun; Laurice Catello; Diana Sanchez; Neha Agarwal; Stephanie Jeong; Youngjin Jin; Yvonne Remache; Andre Goy; Alois Ndlovu; Anthony Ingenito; K Stephen Suh Journal: Melanoma Res Date: 2015-10 Impact factor: 3.599